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The present study aimed to assess the changes in blood factors and ultrasound
measures of atherosclerosis burden patient with mild cognitive impairment (MCI) and
dementia. Peripheral blood samples and ultrasonography findings were obtained for
53 enrolled participants. Flow cytometry was used to evaluate levels of activated
platelets and platelet-leukocyte aggregates (PLAs). The number of platelets expressing
p-selectin was correlated with intima media thickness (IMT) and plaque number in
both the MCI and dementia groups. The number of platelets expressing p-selectin
glycoprotein ligand (PSGL) was strongly correlated with IMT in patients with MCI,
whereas the number of platelets expressing PGSL was correlated with plaque number
rather than IMT in patients with dementia. PLAs was associated with both IMT and
plaque number in patients with MCI but not in those with dementia. Our findings
demonstrate that alterations in IMT and plaque number are associated with an increased
risk of cognitive decline as well as conversion from MCI to dementia and that blood
factor analysis may aid to detect the severity of cognitive decline.
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INTRODUCTION
Aging has been regarded as a major risk factor for neurodegenerative disease (Coutu et al., 2017).
Previous studies have demonstrated a strong association between aging and vascular diseases
(Jeerakathil et al., 2004; Gottesman et al., 2010; Pantoni, 2010). The research has indicated that
factors associated with aging and vascular dysfunction exhibit a cross-sectional relationship with
mental status as determined based on Mini-Mental State Examination (MMSE) score (Atiya
et al., 2003). Recent studies have reported that carotid artery atherosclerosis is associated with a
subsequent risk of new or recurrent cerebrovascular diseases, such as stroke, post-stroke vascular
dementia and mild cognitive impairment (MCI; Knopman et al., 2016; Dearborn et al., 2017; Meyer
et al., 2017). Furthermore, chronic hypoperfusion caused by carotid stenosis has been reported to
play a role in cognitive decline (Ruitenberg et al., 2005; Yurkovetsky et al., 2006).
Dementia represents a major public health concern (Moon et al., 2015), as accumulating
evidence has demonstrated that the incidence and prevalence of dementia increase rapidly
with advancing age (Silvestrini et al., 2009; Petersen et al., 2014; Moon et al., 2015).
Abbreviations: AD, Alzheimer’s disease; ANOVA, analysis of variance; CDR, Clinical Dementia Rating Scale;
FACS, fluorescence-activated cell sorting; FITC, fluorescein isothiocyanate; HDL, high-density lipoprotein;
IgG, immunoglobulin G; IMT, intima-media thickness; LDL, low-density lipoprotein; MCI, mild cognitive
impairment; MMSE, Mini-Mental State Examination; PLA, platelet-leukocyte aggregation; PMA, platelet-monocyte
aggregation; PRP, platelet-rich plasma; PSGL, p-selectin glycoprotein ligand.
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Although it has been difficult to investigate changes in the
incidence and prevalence of dementia due to variations in
diagnostic criteria and methods, a recent epidemiological study
indicated that dementia prevalence and incidence have decreased
in some countries (Wu et al., 2017). Moreover, the number of
patients with dementia remains stable in the aging population of
these countries (Wu et al., 2017). Some evidence has suggested
that vascular risk factors are associated with the onset and
progression of Alzheimer’s disease (AD; Luchsinger et al., 2005;
Deschaintre et al., 2009). In addition, increased cerebrovascular
risk has been associated with more severe dementia and
MCI incidence (Luchsinger et al., 2005; Mioshi et al., 2006;
Deschaintre et al., 2009; Li et al., 2011). Considering the role of
vascular blood factors in patients with MCI, such factors may
also influence the progression of cognitive decline (Iadecola and
Gorelick, 2003). However, there are currently no markers for
the prediction of prognosis or the risk of conversion from MCI
to dementia. Therefore, it is necessary to develop noninvasive
diagnostic methods for the assessment of vascular status (de la
Torre, 2010).
Recent clinical investigations have focused on the relationship
between levels of circulating adhesion factors in peripheral blood
and cerebrovascular diseases (Vermeer et al., 2003; Dearborn
et al., 2017). Platelets and leukocytes play a major role in
atherothrombosis, aggregates of which result in the formation
of atherosclerotic plaque (Folsom et al., 2009; Lievens et al.,
2010; Dopheide et al., 2016; Gerdes et al., 2016). Although other
factors associated with vascular disease can influence cognitive
state, few studies have utilized flow cytometry to investigate
platelet and leukocyte markers in older adults with cognitive
decline. Research has demonstrated a correlation between
circulating adhesion molecules in patients with atherosclerosis
and atherosclerosis factors such as intima-media thickness (IMT)
and the number of plaques, which may aid in determining
the presence and/or extent of cognitive decline (Moon et al.,
2015). In order to determine the potential usefulness of this
correlation for determining diagnoses/prognoses, blood factor
analysis is required. Based on the pathophysiological mechanism
underlying dementia, most relevant studies have aimed to
identify molecular markers based on drug responses (Mioshi
et al., 2006; Jellinger and Attems, 2007; Steinhubl et al., 2007;
Coley et al., 2008). As such, little is known regarding the potential
role of circulating adhesion molecules in patients with vascular
diseases during the early and later stages of cognitive dysfunction.
The present study aimed to assess the relationship between
changes in blood factors and ultrasound findings in patients with
MCI and dementia exhibiting signs of atherosclerosis, and to
suggest the possibility of the most appropriate treatment strategy
for patients with MCI or multiple diagnoses.
MATERIALS AND METHODS
Participants
The present study enrolled 53 participants who had visited
the neurology outpatient clinic of Severance Hospital between
August 2016 and February 2017. Participants with an infection
such as aspiration pneumonia were excluded to avoid parallel
infection, which may also activate platelets or leukocytes. The
control group consisted of nine age- and sex-matched individuals
with no clinical signs of cerebrovascular or cardiovascular
disease such as stenosis or atherosclerosis. Participants of the
patient group were categorized into three subgroups: vessel
damage, MCI and dementia groups. The ‘‘vessel damage’’ group
represents participants who contain one or more cardiovascular
and cerebrovascular diseases containing atherosclerosis, stenosis,
or stent implanted. ‘‘MCI’’ group is basically classified with
based on the Petersen’s criteria (Petersen, 2004). In our case,
we only considered the amnestic MCI for more homogeneous
sample. The basal score of participants are 25–27 on the
MMSE adjusted according to age and education as assessed
for the Korean population. Clinical Dementia Rating Scale
(CDR) values 0.5 and 1.0 were classified into the MCI
group. We also used additional cognitive evaluation battery
the Korean version of Addenbrooke’s Cognitive Examination-
Revised (K-ACE; Mioshi et al., 2006). The type of ‘‘dementia’’
group was included AD only which is diagnosed by department
of neurology in Severance hospital using neuroimaging and
cognitive evaluation (MMSE and CDR) containing Seoul
Neuropsychological Screening Battery (SNSB) widely used in
South Korea.
No differences in atherosclerotic risk profile
(e.g., hypertension, hyperlipidemia and diabetes) were observed.
Fasting levels of total and high-density lipoprotein (HDL)
cholesterol, triglycerides and low-density lipoprotein (LDL)
cholesterol were also measured in each participant. The
characteristics of the participants are shown in Table 1. All
participants underwent cognitive assessment consisting of the
CDR scale and MMSE. Patients with MMSE scores from 25 to
27 and CDR values 0.5 and 1.0 were classified into the MCI
group. Patients with dementia were diagnosed with dementia
and they were classified into the dementia group. All participants
provided written informed consent, and the study protocol was
approved by the Institutional Review Board of the Severance
Hospital (4-2016-0531). All participants gave written informed
consent in accordance with the Declaration of Helsinki.
Ultrasonography
Participants underwent measurement of carotid artery IMT,
plaque morphology and thickness of carotid plaques via
B-mode ultrasonography. Carotid artery plaques were examined
using a high-resolution B-mode ultrasound system (Accuvix
V10, Seoul, South Korea) equipped with a multi-frequency
linear array transducer (5–10 MHz). All measurements
were performed by a technician trained in ultrasound
research in accordance with a standard scanning and reading
protocol.
Carotid artery IMT is defined as a distance from media-
adventitia to lumen-intima interface. Carotid artery IMT
(longitudinal view) was measured offline in a plaque-free region
at the far wall of the common carotid artery (CCA) using a
computerized system. The upper limit of normal for IMT was
defined as 1.0 mm. IMT measures were obtained from walls of
three arterial segments of both carotid arteries; the near and far
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TABLE 1 | Patients characteristics.
Vessel damage Cognitive decline
Control participants stenosis patients MCI Dementia p-value
(n = 9) (n = 29) (n = 11) (n = 14)
Age 65.3 ± 8.1 68.1 ± 12.1 66.3 ± 12.2 70.9 ± 9.7 0.632
Gender 0.188§
Male 11.1 (1) 58.6 (17) 54.5 (6) 28.6 (4)
Female 88.9 (8) 41.4 (12) 45.5 (5) 71.4 (10)
Hypertension 22.2 (2) 31.0 (9) 45.5 (5) 50.0 (7) 0.821§
Diabetes 9.0 (1) 17.2 (5) 27.3 (3) 14.3 (2) 0.420§
Hyperlipidemia 22.2 (2) 24.1 (7) 27.3 (3) 50.0 (7) 0.250§
Total cholesterol (mg/dL) 168.7 ± 42.9 138.6 ± 43.6 138.9 ± 41.4 152.9 ± 43.0 0.400
LDL cholesterol (mg/dL) 76.9 ± 18.2 69.2 ± 32.4 61.8 ± 38.3 76.9 ± 33.7 0.742
HDL cholesterol (mg/dL) 67.0 ± 40.5 50.3 ± 13.1 54.0 ± 14.9 55.1 ± 17.7 0.344
MMSE score 29 ± 0 25.4 ± 3.2 24.7 ± 2.3 20.5 ± 4.3 0.392
Data are expressed percentage as mean ± SD. The each patient number is presented in parenthesis. §Derived from Chi-squared test.
wall of the proximal 10 mm of the internal carotid artery, the
near and far wall of the carotid bifurcation beginning at the tip
of the flow divider and extending 10 mm proximally, and the
near and far wall of the arterial segment extending 10–20 mm
proximally to the tip the flow divider into the CCA (Prati et al.,
2008).
In accordance with theMannheimConsensus, carotid plaques
were defined as focal protruding structures into the lumen with a
size of at least 0.5 mm or 50% of the IMT where is over 1.5 mm
(Touboul et al., 2007). The lesions with an IMT ≥ 1.1 mm were
defined as atheromatous plaques. Thickness of carotid atheroma
to measure and count the plaques was measured in a longitudinal
and vertical view for screening accurate plaque. The plaques were
measured everywhere.
Flow Cytometry
Blood samples were collected into Vacutainer tubes containing
0.5 mL of 3.2% buffered sodium citrate, immediately following
which the citrated blood sample was added to a fixation solution
to minimize ex vivo platelet activation and prepared for flow
cytometry. Whole blood samples were used to assess platelet
activity. Whole blood resuspended in Tyrode’s solution was
incubated with phycoerythrin (PE)-conjugated anti-CD41a
for immunological identification of platelets. The samples
were simultaneously incubated with fluorescein isothiocyanate
(FITC)-conjugated anti-CD62p or FITC-conjugated anti-
CD162 at saturating concentrations for 15 min at room
temperature in the dark. Levels of platelet-bound anti-CD62p
or -CD162 were determined by analyzing 50,000 platelets for
FITC fluorescence. Results were expressed as a percentage of
antibody-positive platelets.
Red blood cell-lysed blood samples were used to determine
leukocyte levels, which were identified based on the forward
and sideward scatter properties of PE-CD45-positive leukocytes.
Monocytes and lymphocytes were identified based on strong
expression of PE-CD14 and PE-CD154, respectively. The
presence of platelet-leukocyte aggregates was assessed during
the detection of CD42b-FITC-labeled platelets. FITC-conjugated
immunoglobulin G (IgG) and PE-conjugated IgG antibody
were used for isotype control experiments. A minimum of
50,000 cell events was analyzed in each assay. The percentages
of platelet-monocyte and platelet-lymphocyte complexes were
calculated. All antibodies used were purchased from BD
Biosciences (New Jersey, NJ, USA). Blood samples were analyzed
using LSRII (Becton Coulter, San Jose, CA, USA).
Statistical Analysis
Participant characteristics and plaque thickness are presented
as mean ± SD. Fluorescence-activated cell sorting (FACS)
and ELISA values are presented as medians. The clinical
characteristics of each group were compared using the
Mann–Whitney nonparametric test. Statistical significance
among groups was determined via one-way analysis of
FIGURE 1 | The distribution of participants and atherosclerotic condition.
(A) Of participant, patients groups are three. Without cognitive decline,
patients with atherosclerosis only are 57.1% of total patients. With
atherosclerosis, patients with mild cognitive impairment (MCI) are composed in
32.1% and patients with dementia are constituted in 14.3%. (B) Intima-media
thickness (IMT) is shown as mean ± SD. Differences of IMT is significant
between dementia and control group. Also it is significant between dementia
and MCI. (C) Numbers of plaques are shown as mean ± SD. There are
significant differences between control and MCI; control and dementia; and
MCI and dementia. ∗p < 0.05 vs. control group, ∗∗p < 0.01 vs. control group.
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FIGURE 2 | Expression of circulating blood factors by fluorescence-activated cell sorting (FACS) analysis. (A) Circulating levels of monocyte aggregated with
platelets in each group. (B) Circulating levels of leukocyte aggregated with CD40Ligand (CD154) in each group. (C) Circulating levels of leukocyte aggregated with
p-selectin glycoprotein ligand (PSGL; CD162) in each group. The data presents with % as an event number per gate by FACS analysis. Bars represent median
values, and the error bar, the standard deviation. ∗p < 0.05 vs. control group, ∗∗p < 0.01 vs. control group, ∗∗∗p < 0.001 vs. control group. NS, not significant.
variance (ANOVA). Probability values were two-tailed, and
values of p < 0.05 were considered statistically significant
(SPSS, Windows version 17.0, Chicago, IL, USA). Pearson
correlation coefficients were used to assess the association
between ultrasound findings (IMT and plaque number) and
changes in blood factors associated with atherosclerotic vessel
dysfunction. Values of the coefficient constant r and r2 are
provided. A value of p ≤ 0.05 was regarded as significant (SPSS,
Windows version 17.0, Chicago, IL, USA).
RESULTS
Clinical Characteristics and Ultrasound
Findings of Control and Patient Groups
In the present study, there was no significant difference in
vascular risk factors among the control, vessel damage, MCI
and dementia groups. Moreover, there were no significant
differences among the three groups with regard to total
cholesterol (p = 0.4), HDL (p = 0.7421) and LDL (p = 0.3439).
Participant characteristics are detailed in Table 1. Of all patients
with vessel damage diagnosed with carotid vascular stenosis
or atherosclerosis, patients with vessel damage without any
cognitive dysfunction comprise 57.1%; patients with MCI is
32.1%; and patients with dementia is 14.3% (Figure 1A).
Particularly, all of patient with MCI had been also with vessel
damage. The IMT was significantly thicker in the dementia
(mean thickness: 0.809 ± 0.097 mm) group than in the control
group (mean thickness: 0.643 ± 0.123 mm), but not in the MCI
group (mean thickness: 0.743± 0.226mm; Figure 1B). However,
plaque numbers were significantly increased in both theMCI and
dementia groups relative to values for the control group (control:
2.5 ± 0.7 vs. MCI: 9.5 ± 6.6, p = 0.0061; control vs. dementia:
6.8± 4.2, p = 0.0012; Figure 1C).
Changes in Levels of Circulating Adhesion
Blood Factors in Patients with MCI and
Dementia
FACS analysis of circulating blood factors associated with
platelet-leukocyte aggregation (PLA) revealed that specific
changes in PLA level in each MCI or dementia group (Figure 2).
The levels of platelet-monocyte aggregates (PMA) as determined
by CD154-CD14 double-staining is lower in dementia group
compared to control, but not significant difference in MCI group
(Figure 2A). In contrast, the level of PLA (CD154-CD45) is
higher in MCI group, but not significant change in dementia
group (Figure 2B). In case of another PLA (CD162-CD45), there
was significant decrease in dementia group compared to control.
It was different from the result in MCI group presenting no
significant change compared to control (Figure 2C).
The number of platelets expressing p-selectin (CD62p)
by FACS was increased in dementia group whereas the
number of platelets expressing p-selectin glycoprotein ligand
(PSGL; CD162) was high both in MCI and dementia group
(Figures 3A,B). The level of p-selectin detected on the surface of
active platelets significantly increased in the vessel damage group
and MCI group, based on changes in platelet-rich plasma (PRP)
levels as determined via ELISA. The level of p-selectin and PSGL
in plasma was higher in the MCI group than in the control group
(Figures 3C,D).
Associations between Vessel Status and
Circulating Blood Factors in Patients with
Cognitive Decline
The correlation between cognitive function and circulating
adhesion factors was analyzed as shown in Table 2. The number
of platelets expressing p-selectin was correlated with IMT and
plaque numbers in both the MCI and dementia groups. The
number of platelets expressing PSGLwas strongly correlated with
IMT, but not with plaque numbers, in MCI group. In contrast,
the number of platelets expressing PSGL was correlated with
plaque number rather than IMT in dementia group. Unlike in the
dementia group, factors associated with blood aggregation and
vessel dysfunction such as CD40Ligand (CD154), PLA and PMA,
were correlated with IMT and plaque number in the MCI group
(Table 2). In the MCI group, IMT was significant correlation
with most of circulation blood factors except of the level of PMA.
Plaque number in MCI group was also significantly correlated
with p-selectin, PLA and PMA (Table 2). In the dementia group,
IMT was significant correlation with the level of p-selectin only.
In contrast, plaque number was a significant correlation with
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FIGURE 3 | CD62p and CD162 expression in cell surface marker and soluble level. (A,B) Level of platelet surface expressing CD62p (p-selectin) or CD162 (PSGL)
was evaluated by FACS analysis. (C,D) Level of CD62p or CD162 in plasma was evaluated by ELISA. The data of FACS represents with % as an event number per
gate. The result of ELISA is presented as ng/ml. Bars represent median values, and the error bar, the standard deviation. ∗p < 0.05 vs. control group. NS, not
significant.
p-selectin and strong correlation with PSGL among circulating
adhesion factors (Table 2).
DISCUSSION
In the present study, we demonstrated that alterations in IMT
and plaque number are associated with an increased risk of
cognitive decline as well as risk of dementia. Our results suggest
that ultrasound findings may aid in identifying older individuals
at increased risk for the progression of cognitive decline when
morphological impairment of cerebrovascular structures has
been identified. Moreover, our findings suggest that the presence
of atherosclerotic changes and changes in blood factors such as
PSGL, PLA and PMA can be used to predict MCI and dementia.
In the present study, levels of p-selectin in circulating
platelets, PSGL and circulating PMA were significantly increased
in patients with MCI relative to controls (Figures 2, 3).
The changes in circulating blood factors have been reported
to relate with vascular diseases like as ischemic stroke or
atherosclerosis (Marquardt et al., 2002; Nadar et al., 2004). Based
on this association, several noninvasive measures for evaluating
subclinical atherosclerosis have received intense attention in
clinical and research settings for the predictive diagnosis of
cerebrovascular diseases.
TABLE 2 | Correlation between ultrasonic characters and circulating blood factors.
Correlating pair MCI Dementia
Ultrasonic characters Circulating blood factors r R2 p value r R2 p value
IMT p-selectin 0.810 0.656 0.0149∗ 0.609 0.371 0.0273∗
PSGL 0.951 0.904 0.0036∗∗ −0.207 0.043 0.5653
CD40 Ligand 0.906 0.822 0.0019∗∗ −0.035 0.001 0.923
PLA 0.819 0.671 0.0243∗ 0.333 0.111 0.2667
PMA 0.370 0.137 0.3665 0.191 0.037 0.5317
Number of plaques p-selectin 0.954 0.911 0.0116∗ 0.665 0.442 0.0255∗
PSGL 0.775 0.600 0.0704 0.921 0.849 0.0002∗∗∗
CD40 Ligand 0.333 0.111 0.4656 0.565 0.319 0.0887
PLA 0.808 0.653 0.0278∗ −0.026 0.001 0.9434
PMA 0.905 0.819 0.0347∗ −0.388 0.150 0.1906
Pearson’s correlation coefficients, R squared, and associated p-values are shown. The bold values are representing the significant circulating blood factors in each
ultrasonic character group. ∗p < 0.05 vs. control group, ∗∗p < 0.01 vs. control group, ∗∗∗p < 0.001 vs. control group.
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Researchers have suggested a relationship between
atherosclerotic severity and circulating adhesion blood factors;
atherosclerotic severity and cognitive decline in the above
mentioned reports. With one step further linking between
them, our findings provide insight into the use of blood factor
analysis (using FACS) as well as ultrasonographic evaluation
of vessel status in both clinical and research settings. Changes
in platelet activation and monocyte distribution are observed
in the early stages of atherosclerosis. Such changes are strongly
associated with stroke onset, as demonstrated by various studies
(King et al., 2009; Cardenas et al., 2012; Xiang et al., 2013). The
monocyte receptor CD14 and leukocyte antigen CD45 are best
known for their crucial role in immunity. In addition, CD14 and
CD16 are well-known biomarkers for atherosclerotic disease
progression (Folsom et al., 2009). Research has also suggested
that (PSGL, CD162) is a pro-atherogenic marker of vascular
disease progression (Folsom et al., 2009).
The present study shows that increased IMT was more
frequently observed in patients with MCI, whereas increased
numbers of carotid plaques were more frequently observed in
patients with dementia. The patients with MCI in our study
comprise 32% of all patients with atherosclerosis, and all patients
of the MCI group in the present study had been diagnosed with
carotid vascular stenosis or atherosclerosis (Figure 1). These
findings suppose that vessel damage is followed by MCI. A
lot of findings in previous studies suggest that greater degrees
of carotid atherosclerosis are associated with the progression
from MCI to dementia (Mioshi et al., 2006; Urbanova et al.,
2014; Moon et al., 2015; Knopman et al., 2016; Dearborn
et al., 2017). The very recent study reported that up to
50% of patients develop vascular stenosis, and that anterior
cerebral artery (ACA) plaques are associated with dementia
even after controlling for vascular risk factors (Dearborn et al.,
2017). Other researches have suggested that atherosclerosis plays
a role in cognitive impairment, particularly in older adults
(Jellinger and Attems, 2007; White et al., 2016). Such research
has further demonstrated a converging relationship between
degenerative vascular dysfunction and cognitive dysfunction.
In our study, most patients with MCI exhibit atherosclerotic
vessel abnormalities, such as increased IMT and plaque numbers,
increasing the risk for progression to dementia. Especially in
aged people, it is reported to estimate that 15%–42% of people
over the age of 65 years exhibit some form of MCI, and that
approximately 5%–15% of patients with MCI go on to develop
dementia (Winblad et al., 2004; Petersen et al., 2014). Recent
evidence has revealed that vessel dysfunction contributes to AD
as well as vascular dementia (Murray et al., 2011). In this previous
study, the authors reported an IMT cutoff value of 0.805 for the
prediction of MCI development (baseline: 0.825 mm; Murray
et al., 2011). Diagnosis of dementia in such patients is required
in order to ensure the appropriate therapeutic guidelines and
treatment are utilized (Wu et al., 2017).
Our results indicate that intima thickness and plaque number
are associated with higher levels of p-selectin, as the evidence
that platelets are engaged in the formation of PLAs (Steinhubl
et al., 2007). In the dementia group of the present study,
which included individuals with dementia, plaque numbers
corresponded strongly with levels of PSGL-positive platelets.
Control of plaque numbers with appropriate therapy such as
statin treatment may thus delay or prevent the progression of
cognitive decline to dementia. Our findings also indicated that
carotid atherosclerosis correlates with MCI as well as increased
numbers of PSGL-expressing platelets. Analysis of blood factors
using ultrasonography may aid clinicians in determining the
most appropriate treatment strategy for patients with cognitive
decline with vessel disease.
The present study has some limitations that need
consideration. First, longer follow-up is required to verify our
findings. We are currently preparing a 3-year follow-up study
including the participants of the present study and additional
volunteers. Second, as the sample size was rather small, future
studies should enroll a larger population. Future FACS studies
should also aim to determine a cutoff value for each blood cell
population for the prediction of progression from cognitive
decline to dementia in older adults with cardio/cerebrovascular
disease. Our simple assessment of vascular risk factors does
not seem to be a fully satisfactory approach for adequately
counteracting the risk of developing dementia, when compared
to other large-scale studies (Coley et al., 2008; Luzzi et al.,
2010). Nevertheless, we suggest that analysis of circulating
adhesion factors may aid in predicting the risk of progressive
cognitive impairment. Additionally, aggressive treatments for
vascular disease should be considered for individuals with a
predisposition toward dementia. Despite these limitations, our
findings provide a basis for further study regarding biomarkers
of both cerebrovascular disease and cognitive dysfunction.
In conclusion, our findings demonstrate that circulating
adhesion molecules level and interaction between factors present
significant differences in patient with MCI or dementia.
Alterations in IMT and plaque number are associated with an
increased risk of cognitive decline as well as conversion from
MCI to dementia. These results suggest that ultrasound findings
may aid in identifying older individuals at increased risk for
the progression of cognitive decline in when cerebrovascular
damaged. Moreover, our findings suggest that the presence of
atherosclerotic changes and changes in blood factors such as
p-selectin, PSGL, PLA and PMA can be useful candidates to
monitor the severity of cognitive decline.
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